Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern
Recommend:
0

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
Recommend :
0
React to this article
Latest news
Date Title
<1m ago TENNECO : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)
1m ago RUSFOREST : Announces Sale of Ystad Pellets AB
2m ago BUDWEISER : Launches 2014 ‘Made for Music’ Campaign; Unveils “Made Underground” Series to Create the Ultimate Band of Street Performers from around the World
3m ago AFH FINANCIAL : Acquisition of Finlay Gow
3m ago CONDOR RESOURCES : Stock Options Granted
3m ago VTION WIRELESS TECHNOLOGY : DGAP-Adhoc: Vtion maintained profitability despite lower revenues
4m ago RESEARCH AND MARKETS : Global ATM Market Report: 2014 Edition
6m ago NTDC to Launch 'Tour Abuja City' Project in August
6m ago NATIONAL GRID : *s&p capital iq raises national grid price target to 900 (789) pence - 'hold'
6m ago STAFFING : eVerifile and eStaff365 Announce Strategic Partnership
Latest news
Advertisement
Hot News 
ST PETER PORT CAPITAL : Says Net Asset Value Fell Due To Strong Pound
STADIUM : Buys United Wireless For Up To GBP8 Million Cash And Shares
GEONG : Announcement in Relation to the CFO of GEONG
FLOWGROUP : Director/PDMR Shareholding
MDM ENGINEERING : and Foster Wheeler merger approval from Tanzanian Competition Commission
Most Read News
1d ago WAL MART STORES : Man Charged With Arson In Fire At Stevens Church
1d ago NORFOLK SOUTHERN : Columbia Street Closing For Repairs
1d ago MOODY : Blues ; Guiding Pennsylvania Out Of The Recession And Its Consequences, As Well As The Gathering Storm Of Pension Payments, Requires Creative...
8h ago QUESTERRE ENERGY : updates Montney activities
1h ago Hague court orders Russia to pay over $50 billion in Yukos case
Most recommended articles
7m ago Potential Argentine debt default looms as July 30 approaches
8m ago Ryanair lifts profit forecast as quality drive pays off
10m agoDJGOLDMAN SACHS : Correction to Greenberg Story on Friday
12m ago PRICE & TIME : Key Couple of Days for USD/CAD
17m agoDJBNP PARIBAS : 2Q 2014 -- Forecast
Dynamic quotes  
ON
| OFF